ADPTHealthcare · Diagnostics & ResearchThe 9 Wall Street analysts covering Adaptive Biotechnologies Corp. hold a median 12-month price target of $30 — +16.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Adaptive Biotechnologies Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ADPT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.1% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $25 → $32 |
| 29 Sept 2026 | Goldman Sachs | Initiates | Buy | $35 |
| 22 Sept 2026 | BTIG | Maintains | Buy | — |
| 22 Sept 2026 | BTIG | Maintains | Buy | $25 → $34 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | $20 → $28 |
| 4 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 30 July 2026 | BTIG | Maintains | Buy | — |
| 30 July 2026 | BTIG | Maintains | Buy | $24 → $25 |
| 30 July 2026 | Guggenheim | Maintains | Buy | — |
| 30 July 2026 | Guggenheim | Maintains | Buy | $22 → $25 |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 30 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $20 → $22 |
| 30 July 2026 | TD Cowen | Maintains | Buy | — |
| 30 July 2026 | TD Cowen | Maintains | Buy | $25 → $28 |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | $18 → $20 |
| 9 July 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 29 June 2026 | Guggenheim | Maintains | Buy | — |
| 17 June 2026 | BTIG | Reiterates | Buy | — |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 6 May 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADPT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Adaptive Biotechnologies Corp. returned +64.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 11% of US stocks
Cheaper than 3% of US stocks
Cheaper than 97% of US stocks
Higher than 70% of US stocks
Higher than 84% of US stocks
Higher than 21% of US stocks
Higher than 15% of US stocks
Higher than 25% of US stocks
Higher than 33% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Adaptive Biotechnologies Corp. has a market value of $4.0B and an enterprise value of $4.2B.
Revenue in the twelve months to 30 June 2026: $308.1M. The latest quarter grew 21.5% year on year.
Net income over the same four quarters: −$64.0M, a −20.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.41.
Free cash flow in the twelve months to 30 June 2026: −$24.0M.
Trailing P/E: −64.8×; forward P/E: −140.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Adaptive Biotechnologies Corp. employs 624 people — $494K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Adaptive Biotechnologies Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Adaptive Biotechnologies said it will report third-quarter 2026 financial results after market close on November 4, 2026. Management will host a corresponding webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Why it matters — ADPT watchers can follow the scheduled results release and management’s webcast for the company’s third-quarter update.
Adaptive Biotechnologies highlighted a new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society's 23rd Annual Meeting in Glasgow on behalf of IMS and the International Myeloma Working Group. The company emphasized the role of its highly sensitive minimal residual disease (MRD) testing in this new definition.
Why it matters — The inclusion of highly sensitive MRD testing in an international consensus definition of cure could elevate the relevance and adoption of Adaptive Biotechnologies' diagnostic platform in multiple myeloma care.
Adaptive Biotechnologies highlighted updates to the NCCN Guidelines for Multiple Myeloma that establish a dedicated framework for routine MRD assessment and specifically reference clonoSEQ as an FDA-cleared assay, with 10^-6 sensitivity now preferred across the patient journey.
Why it matters — ADPT watchers would care because the updated guidelines strengthen and specifically reference the company's clonoSEQ assay for MRD testing, potentially reinforcing its role in myeloma care.
Adaptive Biotechnologies Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The item reports on the company's participation in the industry conference.
Why it matters — ADPT watchers would care because a transcript of management's conference presentation can offer insight into the company's current business outlook and strategy directly from its leadership.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced it will participate in the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The commercial-stage biotechnology company focuses on translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment.
Why it matters — Participation at a major healthcare investment conference gives Adaptive Biotechnologies a platform to present its business to investors and analysts, which ADPT watchers will follow for potential updates on the company's clinical and commercial progress.
The 9 Wall Street analysts covering Adaptive Biotechnologies Corp. have a median 12-month price target of $30, with estimates ranging from $21 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Adaptive Biotechnologies Corp., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Adaptive Biotechnologies Corp. 73 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Adaptive Biotechnologies Corp. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +16.1% from the last close, and Ticker Nerd's factor model ranks Adaptive Biotechnologies Corp. 73 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Adaptive Biotechnologies Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $35 over the next 12 months.
Adaptive Biotechnologies Corp. returned +64.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026". Adaptive Biotechnologies said it will report third-quarter 2026 financial results after market close on November 4, 2026. Management will host a corresponding webcast conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Adaptive Biotechnologies Corporation Common Stock represents the equity of Adaptive Biotechnologies Corporation, a commercial-stage biotechnology company focused on immune medicine. The company develops products and services that use immunosequencing, proprietary chemistry, computational biology, and machine learning to analyze the adaptive immune system and support clinical diagnostics, life sciences research, and drug discovery. Its portfolio includes clonoSEQ, a test used to detect and monitor minimal residual disease in cancer patients, along with immunoSEQ-based offerings for immune profiling and research applications. Adaptive Biotechnologies serves healthcare providers, pharmaceutical partners, researchers, and biotech collaborators across oncology and broader immunology-related markets. Headquartered in Seattle, Washington, the company plays a specialized role in translating immune system data into tools for disease detection and treatment support.
CEO Mr. Chad M. Robins M.B.A. · 624 employees · United States · https://www.adaptivebiotech.com
